Ruxolitinib Cream for the Treatment of Patients With Alopecia Areata: A 2-Part, Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study

There are currently no universally effective or FDA-approved treatments for alopecia areata (AA). Oral ruxolitinib has shown efficacy in extensive AA. Ruxolitinib cream would potentially avoid systemic side effects.

Source: Journal of the American Academy of Dermatology - October 13, 2019 Category: Dermatology Authors: Elise A. Olsen, Deanna Kornacki, Kang Sun, Maria K. Hordinsky Source Type: research